Jewett A, Kos J, Kaur K, Safaei T, Sutanto C, Chen W, et al. Natural killer cells: diverse functions in tumor immunity and defects in pre-neoplastic and neoplastic stages of tumorigenesis. Mol Ther. 2020;16:41–52.

CAS  Google Scholar 

Yu Y. The function of NK cells in tumor metastasis and NK cell-based immunotherapy. Cancers (Basel). 2023;15(8):2323.

Article  PubMed  Google Scholar 

López-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. Cancer Cell. 2017;32(2):135–54.

Article  PubMed  Google Scholar 

Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Ann Transl Med. 2019;7(5):105.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bi J, Tian Z. NK cell exhaustion. Front Immunol. 2017;8:760.

Article  PubMed  PubMed Central  Google Scholar 

Zhang W, Zhao Z, Li F. Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy. Mol Immunol. 2022;144:58–70.

Article  CAS  PubMed  Google Scholar 

Kim HA, Kim H, Nam MK, Park JK, Lee MY, Chung S, et al. Suppression of the antitumoral activity of natural killer cells under indirect coculture with cancer-associated fibroblasts in a pancreatic TIME-on-chip model. Cancer Cell Int. 2023;23(1):219.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jia H, Yang H, Xiong H, Luo KQ. NK cell exhaustion in the tumor microenvironment. Front Immunol. 2023;14:1303605.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu W, Wang G, Huang D, Sui M, Xu Y. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol. 2019;10:1205.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zeng Y, Lv X, Du J. Natural killer cell–based immunotherapy for lung cancer: challenges and perspectives (Review). Oncol Rep. 2021;46(5):232.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hess JB, Sutherland KD, Best SA. Exploring natural killer cell immunology as a therapeutic strategy in lung cancer. Transl Lung Cancer Res. 2021;10(6):2788–805.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang S, Liu W, Hu B, Wang P, Lv X, Chen S, et al. Prognostic significance of tumor-infiltrating natural killer cells in solid tumors: a systematic review and meta-analysis. Front Immunol. 2020;11:1242.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu HH, Feng Y, Hu XS. Emerging immunotherapy targets in lung cancer. Chin Med J (Engl). 2020;133(20):2456–65.

Article  CAS  PubMed  Google Scholar 

Chabannon C, Mfarrej B, Guia S, Ugolini S, Devillier R, Blaise D, et al. Manufacturing natural killer cells as medicinal products. Front Immunol. 2016;7:504.

Article  PubMed  PubMed Central  Google Scholar 

Ben-Shmuel A, Biber G, Barda-Saad M. Unleashing natural killer cells in the tumor microenvironment-the next generation of immunotherapy? Front Immunol. 2020;11:275.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17(19):6287–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benson DM Jr., Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and Lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011;118(24):6387–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao Y, Wang X, Jin T, Tian Y, Dai C, Widarma C, et al. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduct Target Ther. 2020;5(1):250.

Article  PubMed  PubMed Central  Google Scholar 

Russell É, Conroy MJ, Barr MP. Harnessing natural killer cells in non-small cell lung cancer. Cells. 2022;11(4):605.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

Article  PubMed  Google Scholar 

Lin M, Luo H, Liang S, Chen J, Liu A, Niu L, et al. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. J Clin Invest. 2020;130(5):2560–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim EJ, Cho YH, Kim DH, Ko DH, Do EJ, Kim SY, et al. A phase I/IIa randomized trial evaluating the safety and efficacy of SNK01 plus pembrolizumab in patients with stage IV non-small cell lung cancer. Cancer Res Treat. 2022;54(4):1005–16.

Article  CAS  PubMed  Google Scholar 

Park HJ, Kim YM, Jung JS, Ji W, Lee JC, Choi CM. Two-year efficacy of SNK01 plus pembrolizumab for non-small cell lung cancer: expanded observations from a phase I/IIa randomized controlled trial. Thorac Cancer. 2022;13(14):2050–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010;59(12):1781–9.

Article  PubMed  PubMed Central  Google Scholar 

Jia L, Chen N, Chen X, Niu C, Liu Z, Ma K, et al. Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy. Front Immunol. 2022;13:1074906.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang YJ, Park JC, Kim HK, Kang JH, Park SY. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study. Anticancer Res. 2013;33(5):2115–22.

CAS  PubMed  Google Scholar 

Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, et al. Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clin Cancer Res. 2020;26(20):5368–79.

Article  CAS  PubMed  Google Scholar 

Iyoda T, Shimizu K, Kawamura M, Shinga J, Watanabe T, Fukunaga K, et al. Augmenting granzyme B-expressing NK cells by invariant NKT ligand-loaded apcs in patients with postoperative early stage non-small cell lung cancer: results of a randomized phase II study. Immunohorizons. 2023;7(1):1–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin M, Liang SZ, Wang XH, Liang YQ, Zhang MJ, Niu LZ, et al. Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunol Res. 2017;65(4):880–7.

Article  PubMed  Google Scholar 

Calvo T, Reina-Ortiz C, Giraldos D, Gasc